| Literature DB >> 30455964 |
A Akol1, F Makumbi2, J N Babirye2, J S Nalugya3, S Nshemereirwe4, I M S Engebretsen1.
Abstract
BACKGROUND: Integrating child and adolescent mental health (CAMH) into primary health care (PHC) using the WHO mental health gap action program (mhGAP) is recommended for closing a mental health treatment gap in low- and middle-income countries, but PHC providers have limited ability to detect CAMH disorders. We aimed to evaluate the effect of PHC provider mhGAP training on CAMH disorder identification in Eastern Uganda.Entities:
Keywords: Adolescent; Africa; child; mental health; mhGAP; primary care
Year: 2018 PMID: 30455964 PMCID: PMC6236215 DOI: 10.1017/gmh.2018.18
Source DB: PubMed Journal: Glob Ment Health (Camb) ISSN: 2054-4251
Fig. 1.The Gateway Provider Model of youth access to mental health services, from Stiffman et al. (2004).
Fig. 2.CONSORT flow diagram.
Characteristics of clinics by study arm
| Total | Intervention N (%) | Control N (%) | |
|---|---|---|---|
| 18 (100) | 18 (100) | ||
| District | 0.480 | ||
| Mbale | 11(61.1) | 13 (72.2) | |
| Sironko | 7 (38.9) | 5 (27.8) | |
| Under 19 patient visits | |||
| Total | 17705 (100) | 22987 (100) | <0.001 |
| Baseline | 4310 (24.3) | 5003 (21.8) | |
| Follow-up month 1 | 4210 (23.8) | 5752 (25.0) | |
| Follow-up month 2 | 4773 (27.0) | 7084 (30.8) | |
| Follow-up month 3 | 4412 (24.9) | 5148 (22.4) |
Background characteristics of patients 1–18 years by study arm
| Baseline month | Study month 1 | Study month 2 | Study month 3 | |||||
|---|---|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | Intervention | Control | Intervention | Control | |
| Age group | ||||||||
| 1–4 | 1122 (26.0) | 1391 (27.8) | 1064 (25.3) | 1508 (26.2) | 1358 (28.5) | 2109 (29.8) | 1159 (26.3) | 1523 (29.6) |
| 5–9 | 1014 (23.5) | 1202 (24.1) | 984 (23.4) | 1513 (26.3) | 1257 (26.3) | 1925 (27.2) | 1285 (29.1) | 1393 (27.1) |
| 10–14 | 1249 (29.0) | 1323 (26.4) | 1244 (29.5) | 1712 (29.8) | 1288 (27.0) | 1745 (24.6) | 1061 (24.0) | 1160 (22.5) |
| 15–18 | 925 (21.5) | 1087 (21.7) | 918 (21.8) | 1019 (17.7) | 870 (18.2) | 1305 (18.4) | 907 (20.6) | 1072 (20.8) |
| Sex | ||||||||
| Male | 1662 (38.6) | 1944 (38.9) | 1690 (40.1) | 2282 (39.7) | 1870 (39.2) | 2746 (38.8) | 1647 (37.3) | 1932 (37.5) |
| Female | 2524 (58.6) | 2958 (59.1) | 2487 (59.1) | 3397 (59.0) | 2796 (58.6) | 4254 (60.0) | 2729 (61.9) | 3184 (61.9) |
| Missing | 124 (2.9) | 101 (2.0) | 33 (0.8) | 73 (1.3) | 107 (2.2) | 84 (1.2) | 36 (0.8) | 32 (0.6) |
| District | ||||||||
| Mbale | 3055 (70.9) | 3818 (76.3) | 3043 (72.3) | 3990 (69.4) | 3135 (65.7) | 5362 (75.7) | 2939 (66.6) | 3385 (65.8) |
| Sironko | 1255 (29.1) | 1185 (23.7) | 1167 (27.7) | 1762 (30.6) | 1638 (34.3) | 1722 (24.3) | 1473 (33.4) | 1763 (34.2) |
CAMH profile by month and study arm
| Baseline Month ( | Study month 1 ( | Study month 2 ( | Study month 3 ( | Totals ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Int | Control | Int | Control | Int | Control | Int | Control | Int | Control | |
| Anxiety disorders | 0 | 1 | 2 | 0 | 5 | 2 | 4 | 2 | 11 | 5 |
| Depressive disorders | 0 | 0 | 1 | 0 | 5 | 0 | 0 | 1 | 6 | 1 |
| Elimination disorders | 0 | 0 | 0 | 0 | 2 | 0 | 4 | 0 | 6 | 0 |
| Intellectual disability | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Schizophrenic spectrum | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 2 |
| Somatic symptom | 6 | 2 | 5 | 3 | 0 | 0 | 1 | 3 | 12 | 8 |
| Trauma and stressor | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 4 | 2 |
| Totals | 8 | 4 | 13 | 4 | 12 | 4 | 12 | 6 | 46 | 18 |
int, intervention arm.
64 diagnoses were recorded from 63 unique patients.
Percent of clinics with CAMH diagnosis by study arm
| Study Month | Percent of clinics with CAMH diagnosis | Fishers Exact test | |
|---|---|---|---|
| Intervention | Control | ||
| Baseline month | 33.3 | 22.2 | 0.711 |
| Follow-up month 1 | 38.9 | 11.1 | 0.121 |
| Follow-up month 2 | 33.3 | 22.2 | 0.711 |
| Follow-up month 3 | 44.4 | 22.2 | 0.289 |
| Follow-up months 1–3 | 72.2 | 38.9 | 0.092 |
Logistic regression of a CAMH diagnosis between study arms (controlling for age and sex, and accounting for clustering effects at clinic level)
| OR (95%CI) | aOR (95% CI) | |
|---|---|---|
| Baseline month | 2.57 (0.78–8.55) | 2.57 (0.86–7.69) |
| Follow-up month 1 | 4.16 (1.36–12.78) | 4.16 (0.73–23.72) |
| Follow-up month 2 | 3.82 (1.23–11.86) | 3.82 (1.16–12.60) |
| Follow-up month 3 | 2.56 (0.96–6.81) | 2.56 (0.80–8.21) |
| Follow-up months 1–3 | 3.38 (1.83–6.26) | 3.38 (1.34–8.52) |
Accounting for clustering effects at the clinic level.
p < 0.05.